Korea United Pharm Inc. (033270.KS)
KRW 18480.0
(-1.75%)
KRW 18480.0
(-1.75%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 173.48 Billion KRW | 19.41% |
| 2022 | 145.28 Billion KRW | 18.45% |
| 2021 | 122.65 Billion KRW | -2.02% |
| 2020 | 125.19 Billion KRW | -2.64% |
| 2019 | 128.58 Billion KRW | 2.48% |
| 2018 | 125.47 Billion KRW | 12.17% |
| 2017 | 111.86 Billion KRW | 15.52% |
| 2016 | 96.82 Billion KRW | 10.64% |
| 2015 | 87.51 Billion KRW | 5.33% |
| 2014 | 83.09 Billion KRW | 15.14% |
| 2013 | 72.16 Billion KRW | -4.26% |
| 2012 | 75.37 Billion KRW | -15.67% |
| 2011 | 89.38 Billion KRW | 3.86% |
| 2010 | 86.06 Billion KRW | 8.56% |
| 2009 | 79.27 Billion KRW | 18.7% |
| 2008 | 66.78 Billion KRW | 59.06% |
| 2007 | 41.98 Billion KRW | -9.59% |
| 2006 | 46.44 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 71.35 Billion KRW | -10.71% |
| 2024 Q1 | 45.9 Billion KRW | 9.83% |
| 2024 Q2 | 45.63 Billion KRW | -0.57% |
| 2023 Q4 | 41.79 Billion KRW | 2.74% |
| 2023 Q3 | 40.67 Billion KRW | -1.32% |
| 2023 Q2 | 41.22 Billion KRW | 5.39% |
| 2023 Q1 | 39.11 Billion KRW | 7.0% |
| 2023 FY | 173.48 Billion KRW | 19.41% |
| 2022 FY | 145.28 Billion KRW | 18.45% |
| 2022 Q3 | 36.88 Billion KRW | 0.36% |
| 2022 Q1 | 35.09 Billion KRW | 11.15% |
| 2022 Q2 | 36.75 Billion KRW | 4.71% |
| 2022 Q4 | 36.55 Billion KRW | -0.89% |
| 2021 Q3 | 31.56 Billion KRW | 0.16% |
| 2021 Q4 | 31.57 Billion KRW | 0.04% |
| 2021 Q1 | 28 Billion KRW | -14.01% |
| 2021 FY | 122.65 Billion KRW | -2.02% |
| 2021 Q2 | 31.51 Billion KRW | 12.52% |
| 2020 Q1 | 32.16 Billion KRW | -5.89% |
| 2020 Q2 | 28.95 Billion KRW | -9.98% |
| 2020 Q3 | 31.51 Billion KRW | 8.84% |
| 2020 Q4 | 32.56 Billion KRW | 3.36% |
| 2020 FY | 125.19 Billion KRW | -2.64% |
| 2019 Q1 | 32.47 Billion KRW | -16.04% |
| 2019 Q3 | 30.94 Billion KRW | -0.17% |
| 2019 FY | 128.58 Billion KRW | 2.48% |
| 2019 Q4 | 34.17 Billion KRW | 10.43% |
| 2019 Q2 | 30.99 Billion KRW | -4.54% |
| 2018 FY | 125.47 Billion KRW | 12.17% |
| 2018 Q4 | 38.67 Billion KRW | 33.41% |
| 2018 Q1 | 29.52 Billion KRW | 8.6% |
| 2018 Q2 | 28.28 Billion KRW | -4.17% |
| 2018 Q3 | 28.98 Billion KRW | 2.47% |
| 2017 Q1 | 26.2 Billion KRW | 6.42% |
| 2017 Q3 | 30.54 Billion KRW | 9.37% |
| 2017 Q2 | 27.92 Billion KRW | 6.56% |
| 2017 FY | 111.86 Billion KRW | 15.52% |
| 2017 Q4 | 27.18 Billion KRW | -11.0% |
| 2016 Q2 | 23.04 Billion KRW | -7.93% |
| 2016 Q4 | 24.62 Billion KRW | 2.09% |
| 2016 Q3 | 24.12 Billion KRW | 4.67% |
| 2016 FY | 96.82 Billion KRW | 10.64% |
| 2016 Q1 | 25.03 Billion KRW | 0.0% |
| 2015 FY | 87.51 Billion KRW | 5.33% |
| 2015 Q4 | - KRW | -100.0% |
| 2015 Q3 | 20.44 Billion KRW | -4.81% |
| 2015 Q2 | 21.47 Billion KRW | -5.53% |
| 2015 Q1 | 22.72 Billion KRW | 1.43% |
| 2014 Q4 | 22.4 Billion KRW | 10.04% |
| 2014 FY | 83.09 Billion KRW | 15.14% |
| 2014 Q1 | 19.93 Billion KRW | 10.98% |
| 2014 Q3 | 20.36 Billion KRW | -0.08% |
| 2014 Q2 | 20.37 Billion KRW | 2.2% |
| 2013 Q4 | 17.96 Billion KRW | 6.01% |
| 2013 FY | 72.16 Billion KRW | -4.26% |
| 2013 Q1 | 18.59 Billion KRW | 9.31% |
| 2013 Q2 | 18.65 Billion KRW | 0.32% |
| 2013 Q3 | 16.94 Billion KRW | -9.14% |
| 2012 Q3 | 18.59 Billion KRW | -3.38% |
| 2012 Q4 | 17.01 Billion KRW | -8.51% |
| 2012 FY | 75.37 Billion KRW | -15.67% |
| 2012 Q1 | 20.52 Billion KRW | 0.0% |
| 2012 Q2 | 19.24 Billion KRW | -6.26% |
| 2011 Q3 | 21.42 Billion KRW | -3.51% |
| 2011 Q2 | 22.2 Billion KRW | -1.9% |
| 2011 FY | 89.38 Billion KRW | 3.86% |
| 2011 Q1 | 22.63 Billion KRW | 1.26% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q2 | 22.11 Billion KRW | 13.61% |
| 2010 Q1 | 19.46 Billion KRW | -1.07% |
| 2010 Q4 | 22.35 Billion KRW | 1.03% |
| 2010 Q3 | 22.12 Billion KRW | 0.02% |
| 2010 FY | 86.06 Billion KRW | 8.56% |
| 2009 Q4 | 19.67 Billion KRW | -0.26% |
| 2009 FY | 79.27 Billion KRW | 18.7% |
| 2009 Q1 | 18.77 Billion KRW | 4.44% |
| 2009 Q2 | 21.08 Billion KRW | 12.29% |
| 2009 Q3 | 19.73 Billion KRW | -6.43% |
| 2008 Q4 | 17.97 Billion KRW | 15.48% |
| 2008 Q2 | 16.3 Billion KRW | -3.66% |
| 2008 Q1 | 16.92 Billion KRW | 0.0% |
| 2008 FY | 66.78 Billion KRW | 59.06% |
| 2008 Q3 | 15.56 Billion KRW | -4.52% |
| 2007 Q2 | 13.3 Billion KRW | 0.0% |
| 2007 Q3 | 13.3 Billion KRW | -0.02% |
| 2007 FY | 41.98 Billion KRW | -9.59% |
| 2006 FY | 46.44 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -273.052% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 52.353% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 12.771% |
| HANDOK Inc. | 151.36 Billion KRW | -14.614% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -158.072% |
| Yuhan Corporation | 564.5 Billion KRW | 69.267% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 46.157% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -630.565% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 79.244% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -131.195% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 12.803% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -326.789% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -83.555% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -23.167% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -273.052% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -399.738% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -125.842% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 1540.258% |
| JW Holdings Corporation | 446.15 Billion KRW | 61.115% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 16.407% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 73.527% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 48.316% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -120.667% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -130.585% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -140.249% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 5.618% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -273.052% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 41.214% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 74.545% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 48.316% |
| Yuhan Corporation | 564.5 Billion KRW | 69.267% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 14.039% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -144.559% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -75.192% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 48.316% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -18.916% |
| CKD Bio Corp. | 5.01 Billion KRW | -3362.623% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 31.76% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 5.777% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -76.802% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -120.667% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 53.3% |
| Boryung Corporation | 333.26 Billion KRW | 47.944% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -246.66% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 12.803% |
| JW Lifescience Corporation | 51.32 Billion KRW | -238.018% |